CFDE Data Portal | Search ATP6V1B1-AS1

	Label	Description
	ATP6V1B1-AS1 Gene (Entity type)	ENSG00000239322 - ATP6V1B1 antisense RNA 1
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE109913 1 V 2 BLEOMYCIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE210655 1 V 0 CISPLATIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

ATP6V1B1-AS1

ENSG00000239322 - ATP6V1B1 antisense RNA 1

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 3 human up

A Gene Set from LINCS

GSE109913 1 V 2 BLEOMYCIN MOUSE DN

A Gene Set from LINCS

GSE210655 1 V 0 CISPLATIN MOUSE UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.